Suh DJ,Um SH,Herrmann E,et al.Early viral kinetics of telbivudine and entecavir:results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B[J].Antimicrob Agents Chemother,2010,54(3):1242-1247.
[2]
Zeuzem S,Gane E,Liaw YF,et al.Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B[J].J Hepatol,2009,51(11):11-20.
[3]
Zheng MH,Shi KQ,Dai ZJ,et al.A 24-week, parallel-group, open-label,randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients[J].Clin Ther,2010,32(4):649-658.
Weaver CT,Harrington LE,Mangan PR,et al.Th17:an effector CD4 T cell lineage with regulatory T cell ties[J].Immunity,2006,24(6):677-688.
[8]
Trinchieri G.Interleukin-12:a pro inflammatory cytokine with immuno-regulatory functions that bridge innate resistance and antigen-specific adaptive immunity[J].Annu-Rev-Immunol,1995,13(5):251-276.
[9]
Infante-Duarte C,Horton HF,Byrne MC,et al. Microbial lipopeptides induce the production of IL-17 in Th cells[J].J Immunol,2000,165(11):6107-6115.
[10]
Langrish CL,Chen Y,Blumenschein WM,et al.IL-23 drives a pathogenic T cell population that induces autoimmune inflammation[J].J Exp Med,2005,201(2):233-240.
[11]
Park H,Li Z,Yang XO,et al.A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17[J].Nat Immunol,2005,6(11):1133-1141.
[12]
Sa SM,Valdez PA,Wu J,et al.The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis[J].J Immunol,2007,178(4),2229-2240.
[13]
Feng H,Zhang YH.Effect of Chinese medicine therapy for strengthening-Pi and nourishing-Shen in preventing lamivudine induced YMDD mutation and its immunologic mechanism[J].Chin J Integr Med,2010,16(1):19-22.
[14]
Hou W,Kang HS,Kim BS.Th17 cells enhance viral persistence and inhibit T cell cytotoxicity in a model of chronic virus infection[J].J Exp Med,2009,206(2):313-328.
[15]
Ye Y,Xie X,Yu J,et al.Involvement of Th17 and Th1 effector responses in patients with Hepatitis B[J].J Clin Immunol,2010,30(40):546-555.
[16]
Wang LY,Meng QH,Zou ZQ,et al.Increased frequency of circulating Th17 cells in acute-on-chronic hepatitis B liver failure[J].Dig Dis Sci,2012,57(3):667-674.
[17]
Zhang JY,Zhang Z,Lin F,et al.Interleukin-17-producing CD4(+)T cells increase with severity of liver damage in patients with chronic hepatitis B[J].Hepatology,2010,51(1); 81-91.
[18]
杨绍基,任红.传染病学[M].7版.北京:人民卫生出版社,2010.
[19]
Kolls JK,Lindén A.Interleukin-17 family members and inflammation[J].Immunity,2004,21(4):467-476.
[20]
Lai CL,Gane E,Lliaw YH,et al.Telbivudine versus lamivudine in patients with chronic hepatitis B[J].N Engl J Med,2007,357(25):2576-2588.
